Clinical partnerships in the medical cannabis industry are providing clinicians with the practical knowledge they need to make better-informed treatment decisions for their patients.
In more ways than one, the key to growth and expansion in the medical cannabis space is knowledge, and the pursuit of knowledge applies to all stakeholders in the cannabis industry. Patients are taking the time to learn more about how medical cannabis can provide them with new treatments that can help alleviate their symptoms and ailments. Physicians are performing their due diligence to learn the facts about these emerging cannabis treatments. Cannabis companies are learning more about consumer needs and tailoring their product offerings accordingly. Researchers are conducting the leg work that proves the efficacy and legitimacy of cannabis as a medicine. As everyone involved learns more, there is more opportunity for growth in the medical cannabis space.
The medical cannabis industry is growing at a strong and steady pace. According to data collected by Research and Markets, the global industry will be worth more than $37 billion by 2023, up from more than $11 billion in 2017 for a compound annual growth rate of 22 percent. Global Market Insights projects the US medical cannabis market could be worth more than $8 billion by 2024. In Canada, where the medical side of the cannabis industry is now part of a much larger space, medical cannabis alone is still expected to generate between $0.77 and $1.79 billion in sales by the end of 2019, according to Deloitte Canada’s 2018 Cannabis Report.
The barriers to medical cannabis research are finally coming down, and, with a wave of legalization, the medical cannabis industry continues to spread throughout North America, into Europe and beyond. This movement has created more opportunities for researchers and medical institutions to form clinical research partnerships to better understand the needs of patients and the potential of medical cannabis to meet those needs.
Understanding medical cannabis
The therapeutic benefits of medical cannabis have been apparent for decades. However, cannabis spent nearly 100 years under strict prohibition that did little to keep the plant out of the hands of recreational users while significantly hindering our understanding of the drug. Over the past 20 years, medical cannabis research has made significant progress filling in the gaps of our scientific understanding of cannabis. However, there is still much to be learned about the best methods of use, the optimal combinations of cannabinoids and the other factors that govern the efficacy of medical cannabis.
This in itself is the reason why some selected medical cannabis companies are choosing to partner with research groups and academic institutions to conduct clinical trials aimed at developing and refining cannabis products.
Cannabis companies have also partnered with medical clinics that provide medical cannabis products to their patients. This strategy gives researchers and cannabis product developers insight into the needs and experiences of real cannabis patients. With a greater understanding of medical cannabis and the needs of patients, medical cannabis companies can tailor their products to better treat the specific ailments and preferences of those patients. Furthermore, with a higher volume of evidence-based trials and research to draw from, physicians will gain better insight and confidence in medical cannabis treatments, making them more likely to recommend and prescribe those treatments.
In addition to supporting overall research and development, these partnerships also offer strategic avenues for a company’s overall growth. Taking a key leadership role in the advancement of medical cannabis research better positions a cannabis company as a thought leader and innovator in the medical cannabis space, helping it build and solidify its brand reputation and commitment to the medical community.
Clinical partnerships in the medical cannabis industry
In September 2018, Canadian medical cannabis producer Pure Global Cannabis (TSXV:PURE,OTCMKTS:PRCNF,FWB:1QS) announced that, through its subsidiary PureSinse, the company had formed a clinical partnership with Appletree Medical Group. Together the companies will conduct an observational study to describe the effectiveness of medical cannabis strains and cannabinoid-terpene combinations used in real world clinical settings for a variety of medical conditions. The pan-Canadian study will be overseen by a global clinical research organization specialized in harnessing information and data analytics that drive healthcare forward.
The goal of the study is to provide Pure Global with key insights that will shape and inform the development of improved treatments for neuropathic pain, insomnia, anxiety disorders, opioid dependence, PTSD and more.
“Clinic partnerships are part of our mission to brand ourselves to the medical community as a trusted partner for the education and supply of medical cannabis products. We are conducting a real world, evidence-based study on the therapeutic effects of cannabis to give physicians and healthcare professionals the evidence and data they need to help patients choose the best cannabis treatment options,” Pure Global CEO Malay Panchal told the Investing News Network. “This in turn will give healthcare professionals, including physicians, pharmacists, nurses and naturopaths, the confidence to send their patients to PureSinse for their medical cannabis needs.”
Research partnerships like Pure Global and Appletree’s are becoming a more common practise in the medical cannabis industry. Canadian cannabis company Canntrust Holdings (TSX:TRST) announced in September 2018 that the company would be partnering with McMaster University in Hamilton, Ontario, as well as Hamilton Health Sciences’ Michael G. DeGroote Pain Clinic, to conduct clinical trials to research the therapeutic use and clinical effectiveness of cannabinoids. In August 2016, Canadian cannabis giant Aurora Cannabis (NYSE:ACB,TSX:ACB) announced that the company would be working with McGill University to launch an international collaborative medical research project on the therapeutic effects and health outcomes of cannabidiol therapy for chronic pain, anxiety and depression.
When more is understood about the effects and benefits of medical cannabis, everyone wins. Physicians are able to confidently prescribe cannabis as a game-changing alternative to opioids, cannabis producers see greater opportunity for growth in a thriving medical cannabis space and patients gain effective and safe treatment options. The full potential of medical cannabis remains unknown, but many companies are moving towards that potential by securing clinical partnerships.
This article was written according to INN editorial standards to educate investors.
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.